Nucleosome accumulation and reduction of C-reactive protein are associated with the generation of anti-nuclear antibodies in patients with rheumatoid arthritis treated with adalimumab, but not with etanercept

Ann Rheum Dis. 2009 Sep;68(9):1514-6. doi: 10.1136/ard.2008.103291.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adalimumab
  • Antibodies, Antinuclear / biosynthesis
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Rheumatoid / drug therapy*
  • C-Reactive Protein / metabolism*
  • Etanercept
  • Humans
  • Immunoglobulin G / therapeutic use
  • Nucleosomes / metabolism*
  • Receptors, Tumor Necrosis Factor / therapeutic use

Substances

  • Antibodies, Antinuclear
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Immunoglobulin G
  • Nucleosomes
  • Receptors, Tumor Necrosis Factor
  • C-Reactive Protein
  • Adalimumab
  • Etanercept